Migraines Redefined: A Comprehensive Review of Newly Approved Therapies

A major cause of quality-of-life problems worldwide is migraine, which is a common neurological condition. Migraine is a complex illness that involves the development of neurovascular and sensory pathways, along with recurrent headaches which often cause nausea, vomiting, photophobia, and phonophobia. This condition is known as migraine. Even though NSAIDs and triptans are effective, some patients experience cardiovascular risks, poor tolerability, and inadequate response. These limitations apply to traditional treatments. New treatments for migraine have radically changed disease management with the introduction of targeted therapies.' Efforts achieved through the use of (gepant, rimegeparent, and ubrogeproient) and monoclonal antibodies (erenumab, derivazolam, eptinezumac) have been found to be more effective, safe, or detectable. In addition, there are newer formulations including intranasal zavegepant, Symbravo combination therapy and Brekiya alternative which also offers more treatment options for both acute and preventive management. Migraines are targeted by these drugs, which reduce the frequency and severity of migraine-related disorders. They have the promise but still face challenges with cost, accessibility and long-term safety data. To optimize outcomes, personalized approaches must incorporate pharmacological advancements with lifestyle modifications and non-pharmacotherapy interventions. The shift towards precision medicine is evident in the development of migraine therapeutics, which offers a renewed sense of hope for improved patient care and quality of life.